Riddle me this Batman, what does it take to infringe on copyright?

By: Drew Carlson

In late 2022, writer Chris Wozniak sued Warner Brothers, claiming that the 2022 hit film The Batman copied a comic book story he’d proposed thirty years prior. In a 45-page judicial opinion from March 27th, Judge Paul Engelmayer held that the recent movie had not infringed on Wozniak’s copyright and even declared that Wozniak infringed on DC’s copyrights by writing a Batman story.

Was there infringement? If so, from whom?

What’s the situation, Commissioner?

In 2022, The Batman was released in theaters. Set in a corrupt and strife-filled Gotham, the film features a younger Batman investigating a series of murders committed by the Riddler, a long-time Batman villain since the 1940s. Batman solves the villain’s signature riddles to try and foil his destructive plans. The film was a hit with critics and audiences alike, making $370 million in the domestic box office and earning an 85% rating from critics. However, one man was less than pleased.

In 1990, Christopher Wozniak wrote a story called The Ultimate Riddle, later retitled The Blind Man’s Hat. Set in a corrupt and strife-filled Gotham, the story features an older Batman investigating a series of murders committed by the Riddler. Batman solves the villain’s signature riddles to try and foil his destructive plans. Wozniak submitted the story to DC Comics along with a few other publishers (changing the character names to correspond with the company) but none were interested.

However, when Wozniak saw the movie, he believed the film’s premise and large portions of its plot were identical to his own story. He sued Warner Bros. for copyright infringement against his story, leading DC Comics to file a counterclaim against Wozniak for infringement against their Batman property.

Holy Infringement, Batman!

Copyright infringement “occurs when a copyrighted work is reproduced, distributed, performed, publicly displayed, or made into a derivative work without the permission of the copyright owner.” For example, copying someone else’s story or characters is infringement. However, copyright does not protect against more than one artist creating identical works, so long as they do so independently of each other.

When there is no direct evidence of copying, courts can use indirect evidence to infer it. This method requires proving both access and substantial similarity. Proving access shows that it is plausible for the accused infringer to have actually seen the work they supposedly copied. After all, you cannot infringe on a work you have not seen. 

Substantial similarity requires that the two have enough similarities that an ordinary observer would believe that one is imitating the appeal of the other. Some similarity is allowed, but not to the point where similarities become so apparent that the total look and feel of the infringed-upon work has been taken by the infringing one.

However, ideas themselves cannot be copyrighted, only creators’ expression of them.  So, the idea of a boy training a dragon cannot be copyrighted. But, the way dragon training is expressed in both Eragon and How to Train Your Dragon can be copyrighted. When it is inevitable that ideas will be expressed in certain ways, copyright is more lenient to similarities between works. Elements that are common to a type of work are often protected as “scenes-a-faire.” For example, it is not infringing for a western to show the heroes riding into the sunset because such imagery is common.

Did the movie infringe, Batman?

No, it did not. For one, Director Matt Reeves had no access to Wozniak’s story. Wozniak submitted his story to DC Comics and a few other publishers in the 1990s, along with film producer Micheal Uslan in 2008. 

Matt Reeves worked for Warner Brothers, not DC. He claims he did not even contact DC during the film’s writing, nor was he even aware of Wozniak’s story. Instead, he took inspiration from noir films like Chinatown, Taxi Driver, and his own prior knowledge of Batman.  Even if he had contacted DC, the company could not find Wozniak’s story in its archives and its executives were unaware it existed. Producer Micheal Uslan, whom Wozniak pitched his story to, was credited as an executive producer on The Batman. However, Uslan had no actual involvement making the film, and was only credited due to an agreement he made with Warner Bros. in 1988. Thus, the judge found there was no reason to believe Reeves had any access to Wozniak’s story. No access, no infringement.

Additionally, the two stories are not substantially similar. Strip away the parts DC owns (the Batman mythos), and what is left are a collection of story elements that easily qualify as scènes à faire. Both stories depict a loner serial killer lashing out at a corrupt society and leaving riddles to his crimes, while an intrepid hero investigates to stop him. All of these elements are common to the crime genre and have appeared in works like Sherlock Holmes to Dirty Harry.

When the Batman elements are added back, the scenes-a-faire becomes even clearer. The Riddler has been leaving clues for over half a century. Gotham has been depicted as corrupt and crime ridden for decades, and Batman has been solving crimes there since before the Second World War.

In short, the film did not infringe on Wozniak’s story. But did Wozniak infringe on DC’s property by writing a Batman story?

Counterclaim, Old Chum:

DC filed a counterclaim against Wozniak for infringing on their copyright to Batman. Batman is DC’s property, as are his villains, his supporting cast, and even his car! Wozniak did not just write a crime story, he wrote a Batman story. While DC was fine with him writing stories to pitch to them, they did not authorize him to create it for his own personal use.

If Wozniak wanted to overturn this infringement ruling, his best argument would be that his story was fair use. Fair use is a defense to infringement where the accused infringer admits to copying but alleges said copying is “fair.” The defense examines the purpose and character of the usage, the nature of the underlying work, the amount and substantiality of the copied portions, and the effect on the original’s markets. Commercial use weighs against the use being fair. However, uses that are transformative, meaning the new work has a different purpose and thus is not a substitute for the original, are more likely to be fair. The most important factors for a finding of fair use are the purpose of the use, and the effect on the original’s market.

Wozniak’s story was offered to DC as a spec script, and has not been sold to anyone else. Therefore, he could argue that his work had a different purpose (as a spec script) and did not threaten DC’s market. However, the fact that he was trying to sell the story could easily weigh against fair use. Even if he did win, it would cost him valuable time and money after he already lost his main argument.

And The Batman got away:

In short, the filmmakers of The Batman had no access to Wozniak’s story. Most of the similarities between the two are common among works of their genre. Meanwhile, Wozniak’s story used many elements belonging to DC comics, opening him to an infringement claim.

In his decision, Judge Engelmayer granted Warner Bros. and DC’s motions for summary judgment, dismissing the copyright claim against Warner Bros. and granting the one against Wozniak. The only claim left open is DC’s claim of copyright fraud. Wozniak’s lawyer responded by saying, “[w]e respectfully disagree with the court’s decision and are considering our next steps.” Whether the case continues is in the parties’ hands. We’ll just have to tune in, same Bat Time, same Bat Channel.

Are Pig Kidneys Patentable? The Legal Landscape Around The First Genetically Engineered Pig Kidney Transplant

By: Bethany Butler

Last month, doctors at Massachusetts General Hospital successfully transplanted a genetically engineered pig kidney into a 64-year-old patient. Scientists removed porcine genes and added human genes via the CRISPR-Cas 9 gene editing technology. In total, sixty-nine of the pig’s genes were modified prior to transplantation. The surgery took approximately four hours, with the kidney functioning almost immediately after transplantation. eGenesis, a biotechnology company focused on genetically engineered, human-compatible organs, invented this procedure and the resulting genetically engineered kidney. This novel procedure may help to alleviate critical organ shortages in the US, with more than 100,000 Americans currently on the transplant wait list. Scientists hope this procedure will pave the way to more research and clinical applications that may help to alleviate the organ transplant shortage. 

The Legal Landscape

Novel research and clinical applications surrounding xenotransplantation, the transplanting of animal cells/organs to humans, have the potential to revolutionize access to life saving therapies. However, the legal landscape surrounding this science is far from settled. While areas of xenotransplantation of pig organs into humans have been granted patents, the procedure itself has not been approved by the FDA. These procedures, like the one used for the modified pig kidney transplant, are only currently able to move forward using “compassionate use” exceptions granted by the FDA. These exceptions apply to patients with life-threatening conditions where there is no alternative for treatment. 

Another important aspect of the law surrounding xenotransplantation is informed consent. Informed consent is a protection provided by the Health and Human Services regulation, 45 CFR Part 46. The regulation requires that important information, including any risks, be disclosed to the patient before he or she decides to participate in any trials or undergo treatment. Xenotransplantation procedures carry unique risks, such as zoonotic infections and the need for lifelong monitoring and intervention due to the nature of the procedure. Patients must be informed of and consent to all of the unique risks involved with these types of treatments. 

Xenotransplantation and Patent Law

Biological patents are generally utility patents, which allow the patent holder to exclude others from making, selling, using, or importing their biological invention for a specified period of time, currently twenty years in the United States. Companies like eGenesis can own biological patents for genetically modified animal organs and associated methods for xenotransplantation. Currently, these types of patents are protected by law, provided the claimed subject matter is not naturally occuring. US patent law has exceptions to patentable subject matter that are laws of nature, natural phenomena, and products of nature. The Supreme Court found, in the landmark case Association for Molecular Pathology v. Myriad Genetics, Inc., that “a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated.” The case concerned whether the BRCA1 and BRCA2 genes can be patent eligible when isolated. These genes are responsible for tumor suppression and mutations in these genes commonly lead to the development of breast cancer. If the Supreme Court had ruled that Myriad Genetics could patent these gene sequences, that ruling would have effectively prevented any other company from offering diagnostic testing for these genes, thereby monopolizing the breast cancer diagnostic market. The Supreme Court’s decision relied on the statutory provisions in 35 U.S.C. § 101, which addresses patentable subject matter. The court has found exceptions to what is patentable, including laws of nature and natural phenomena. In terms of biological material, if the invention or process is something that naturally occurs, then it is ineligible for patent protection. 

Some eligible biological patents granted in the past include the PCR process and transgenic animals – an animal whose genome has been edited to contain genes from another species. The first transgenic mammal patented was the Harvard Oncomouse, developed by Harvard in the 1980s. This mouse was genetically modified to be more likely to develop cancerous tumors, making it a valuable cancer research subject, and patent eligible. 

Innovation for novel developments in the transplant space, like the genetically modified pig kidney, is encouraged by the patent protection of inventions utilized for xenotransplantation technology. eGenesis has received a number of patents related to the xenotransplantation process, including utility patents for the methods to generate genetically modified animals/cells and for genetically modified animals/tissue/cells used for xenotransplantation.  

The narrowing of biological patents to non-naturally occurring subject matter allows for companies like eGenesis to obtain patents for biological innovations while still protecting research and development efforts, particularly diagnostic testing of carrier genes. Patent eligibility of biological and natural phenomena is currently being addressed in Congress. On June 22, 2023, the US Senate released the Patent Eligibility Reform Act of 2023 (“PERA”). If passed, this act would clarify patent-eligible subject matter and potentially allow for the patenting of solely isolated genes, possibly overriding the Myriad decision. 

While patent eligibility of biological subject matter has the potential to allow for greater innovations, like modified organ transplants, expanding patent-eligible material may lead to negative downstream impacts. Granting monopolies can lead to access issues for diagnostic testing and increasing costs to use isolated genes in research and development efforts. Granting patent protection to biological patents is important and the right balance is necessary to further innovation and facilitate problem solving medical solutions. While patent law is complicated and evolving, novel advancements like the pig kidney transplant are largely driven by innovation incentives and a greater need for medical solutions to the transplant wait list issue.

“Road House” Screenwriter Declares War on Amazon

By: Mayel Andres Tapia-Fregoso

On March 21, 2024, Amazon Studios released its latest blockbuster film “Road House,” a remake of the original 1989 action classic. Following its launch on Amazon Prime Video, Amazon’s streaming platform, the studio revealed that as of April 1, 2024, the film reached 50 million viewers. Yet, despite the film’s apparent success, Amazon’s Road House production has been filled with controversy. On February 27, 2024, R. Lance Hill, the writer of the original Road House (1989) screenplay, filed a lawsuit against Amazon Studios and its subsidiary MGM, alleging copyright infringement. Hill alleges that Amazon ignored his ability to reclaim the rights for his 1986 screenplay, disregarding his rights under law.

The premise of Road House is centered on the story of an ex-UFC fighter, played by Jake Gyllenhaal, who is approached by the owner of the Road House bar offering him a second chance at life. Located in the remote Florida Keys, Gyllenhaal leaves his brawling days behind to protect the bar against a criminal enterprise who seeks to develop the land under the Road House for its own ends. 

Under U.S. Copyright law, a writer must wait thirty-five years from the date of the execution of a copyright grant before terminating the grant. After thirty-five years have passed, the writer can terminate the copyright grant by serving notice to the grantee in writing at least two years in advance of the effective date of termination. The copyright grantee’s rights, including the right to create a derivative work, expire upon effective termination of the grant. A derivative work is a work based on or derived from one or more already existing works. Cinematic adaptations of screenplays are considered derivative works. However, an artist cannot terminate the copyright in a work is made for hire which is when the work is created by an employee as part of the employee’s regular duty or when the work is created as a result of an express written agreement between the creator and the party commissioning the work. The party commissioning the work is considered the author and copyright owner.

Hill wrote the original screenplay in 1986 for the film label United Artists (UA), owned by MGM. According to the lawsuit, Hill did not have an employment or contractual relationship with UA when he wrote the screenplay. Hill entered into a “literary purchase agreement” with UA through his personal company, Lady Amos Literary Works Ltd., who owned the rights to the copyright. Therefore, according to Hill, UA only owned the rights to the screenplay for a limited time.

In November 2021, thirty-five years after Hill completed the original Road House screenplay, he filed the necessary petition with the U.S. Copyright Office and notified Amazon of his intent to terminate the grant of the copyright in two years. According to the complaint, Amazon instituted a self-imposed deadline to complete the Road House remake before the copyright in the original Road House screenplay would revert back to Hill in November 2023. The studio began filming the remake in 2023 until the 118-day-long Screen Actors Guild strike took place, pausing production until November 8, 2023. In his complaint, Hill argues that Amazon took “extreme measures” to finish the film by November 2023 at considerable cost by resorting to using artificial intelligence (AI) to “replicate the voices” of the actors in the remake. However, Amazon still completed the movie in January 2024, two months after the copyright reverted to Hill.

An Amazon spokesperson claimed that the allegations in the complaint were “categorically false” including the allegations regarding Amazon’s use of AI to replicate actor’s voices in the film. However, a person close to the studio suggested that if Amazon exploited actor’s voices by using AI to finish filming the remake, it was during the early stages of production. Studio executives insisted that the filmmakers remove any traces of AI in the finished product. Ultimately, the issue in this case will turn on whether Hill wrote the screenplay while under contract with UA or if he worked on it independently when he sold the rights to UA.Hill’s lawsuit is the latest in a stream of lawsuits by screen writers reclaiming the rights to their screenplays created in the 1980s from major film studios. In 2021, Arthur Miller, the creator of the Friday the 13th (1980) screenplay, successfully reclaimed his copyright in the screenplay by defeating Manny Inc., in a lawsuit decided by the 9th Circuit. In that case the court ruled in favor of Miller because it found that the screenplay was not a work made for hire, allowing him to terminate the transfer of copyright. As more time passes, we will likely see more artists seek to reclaim the rights to their work, giving them freedom to reap the benefits of their work long after the work’s initial creation.

Not So Golden Handcuffs

By: Bella Hood

Wunderkind Sam Bankman-Fried, otherwise known as “SBF”, was sentenced to 25 years in prison and ordered to pay $11 billion on March 28, 2024. A federal court convicted SBF in November on seven counts of fraud, conspiracy, money laundering, and conspiracy to commit commodities and securities fraud.

The former 32-year-old billionaire is the son of two Stanford law professors. After graduating from the Massachusetts Institute of Technology, he worked at Jane Street Capital, a quantitative trading firm. FTX, an abbreviation of “Futures Exchange” was founded by SBF in 2018 as a centralized cryptocurrency exchange supporting futures for all major cryptocurrencies. At his height, SBF’s net worth was said to be around $26 billion. For reference, Beyonce’s is roughly $800 million. SBF also founded his own hedge fund, Alameda Research, which would go on to be a key player in his scheme to defraud investors.

In November 2022, FTX filed for Chapter 11 bankruptcy (handled by Sullivan & Cromwell) which requires the reorganization of the company’s assets and liabilities but does not kill the company outright. Even so, FTX is dead for all intents and purposes and announced in January it would not reopen its exchange and would liquidate all assets.

A New York jury found SBF guilty of all seven criminal counts, including wire fraud and conspiracy to commit wire fraud against FTX customers. Against Alameda Research lenders the court found SBF guilty of conspiracy to commit securities fraud, conspiracy to commit commodities fraud against FTX investors, and conspiracy to commit money laundering.

Congress enacted the wire fraud statute in 1952 as an extension of the 1872 mail fraud statute. In 1987, the Supreme Court broadly held in McNally v. United States that the statute applied to any act “designed to defraud by representations as to the past or present, or suggestions and promises as to the future.” Securities fraud refers to illegal activities that involve the deception of investors or the manipulation of financial markets. The Securities and Exchange Commission is the primary securities regulator in the U.S.

Commodities fraud is the sale or purported sale of a commodity through illegal means and often goes hand in hand with securities fraud. Since 2019, the Fraud Section of the Criminal Division of the U.S. Department of Justice has entered six corporate resolutions relating to violations of the commodities laws with a combined total monetary amount of over $1 billion. Money laundering is the act of disguising financial assets so they can be used without detection of the illegal activity that produced them.

Bernie Madoff, orchestrator of the biggest Ponzi scheme in history, was convicted of 11 federal felony counts, including securities fraud, wire fraud, mail fraud, and money laundering, which earned him a sentence of 150 years in prison.  His net assets in 2009 prior to sentencing totaled at least $823 million. It is estimated that he stole as much as $65 billion. In comparison, SBF was found to have cheated customers and investors of at least $10 billion. Jeffrey Skilling, the failed CEO of Enron at the time of its implosion, was convicted of an impressive 19 crimes, including 12 counts of securities fraud. Skilling was ultimately sentenced to 14 years in prison and ordered to pay $42 million in restitution to victims of the fraud. The energy and commodities trading holding company held $63.4 billion in assets before its stocks tanked.

Though a long line of financial fraudsters paved the way for SBF, the use of cryptocurrency to achieve such scale was largely unheard of. Bitcoin was the first cryptocurrency created and is younger than SBF himself, having launched in 2009. The public should expect to see the federal government go after an increasing number of crypto king copycats in the future in an attempt to strengthen guardrails on the industry.

In September of 2023, a cofounder of OneCoin, a now defunct cryptocurrency exchange, was sentenced to 20 years in prison for creating and promoting a phony cryptocurrency. Just this past month, OneCoin’s former head of legal and compliance, Irina Dilkinska was sentenced to four years in prison and ordered to forfeit over $111 million. Dilkinska pled guilty in November of 2023 to one count of conspiracy to commit wire fraud and one count of conspiracy to commit money laundering. March of 2024 was a busy month for the U.S. government because a jury also found the founder of Terraform Labs, a Singapore-based blockchain protocol and payment platform, liable for defrauding investors in 2021. Binance is yet another example of a cryptocurrency exchange riddled with fraud. In November of 2023 (sensing a trend?), the company and founder pleaded guilty to money laundering and other crimes, costing the company over $4 billion.

Treasury Secretary Janet Yellen set the tone when she told the industry: “Let me be clear, we’re also sending a message to the virtual currency industry more broadly – today and for the future, the virtual currency exchanges and financial technology firms wish to realize the tremendous benefits of being part of the US financial system they must play by the rules. If they do not, the US government will take action.” SBF’s sentence serves as a harbinger of the U.S. government’s approach to cryptocurrency fraud and the harsh punishments to come.

The Legal Battle Behind an Olympic Figure Skating Doping Controversy May Change Anti-Doping Rules

By: Bethany Butler

2022 Olympic Women’s Singles Figure Skating Doping Controversy 

The 2022 Winter Olympics in Beijing were overshadowed by an intense doping scandal in the women’s singles figure skating event. In February 2022, Kamila Valieva, a 15-year-old Russian figure skater (competing under the ROC “Russian Olympic Committee” due to Russia’s previous doping issues), participated in the Olympic figure skating team event. With the help of Valieva’s top scores, the ROC placed first in this event, followed by the United States in second, Japan in third, and Canada in fourth. At the time, the medal ceremony was delayed for this competition. It was later revealed that the results of Valieva’s drug test from the Russian championship a few months prior in December 2021 was the reason behind the delay. Valieva’s sample from the December 2021 competition was found to contain detectable amounts of trimetazidine (“TMZ”), which is a World Anti-Doping Agency banned substance that is thought to help with endurance and recovery. The timing and reporting of this doping violation was unfortunate as it led to issues regarding the results of the team event, and questions of whether Valieva would be allowed to compete in the individual competition. Quickly after the drug testing results came out, the Court of Arbitration for Sport decided that Valieva was ultimately allowed to compete in the individual event in part due to her protected status as a minor and the “untimely notification” of the anti-doping results. In the individual competition Valieva placed fourth while her Russian teammates, Anna Scherbakova and Sasha Trusova, earned the gold and silver medals respectively. Following the Olympics, the main unanswered question was whether Valieva’s scores would be disqualified, and if so, what would happen to the team event standings. 

Legal Battle and Ruling

The legal and procedural landscape surrounding Olympic sports and anti-doping policies involve the International Olympic Committee (“IOC”), the World Anti-Doping Agency (“WADA”) and the Court of Arbitration for Sport (“CAS”). WADA is a foundation initiated by the IOC and coordinates anti-doping efforts across nations. CAS is a mediator in anti-doping cases which handles WADA appeals “under the jurisdiction of World Anti-Doping Code signatories (Code).” In addition, CAS “provides for services to facilitate the settlement of sport-related disputes” and eventually handled the case between Valieva, the Russian Anti-Doping Agency (“RUSADA”), the International Skating Union (“ISU”), and WADA. 

Following delays from the RUSADA investigation into the Valieva case, WADA put the agency on notice that they will appeal the case to CAS if a resolution is not released. Eventually, RUSADA, the ISU, and WADA all appealed the case to CAS which resulted in closed hearings at CAS’s headquarters in Lausanne, Switzerland.  

In January of 2024, almost two years after the 2022 Winter Olympic Games, CAS ruled that Valieva was guilty of an anti-doping violation for her positive TMZ sample. The ruling resulted in a four year ban, retroactive to December 25, 2021, the date of Valieva’s positive test at the 2021 Russian Championship. Valieva’s Olympic results were subsequently disqualified due to this ban, which led many to speculate how the IOC would handle the figure skating team event results. 

Ultimately, the IOC decided to remove Valieva’s results from the cumulative team score and keep all other scores the same. This led to the US and Japan teams moving to the first and second spots, with the ROC team dropping to third, rather than disqualifying the entire team results and moving Canada to the third spot. So far four appeals to CAS, three from Russia and one from Canada, were filed challenging the ISU’s amended team event standings.  

The handling of Valieva’s case led to many criticisms, primarily related to using a teenage athlete as a scapegoat in a flawed system. Valieva was the only one punished in this case, even though she was 15 years old at the time. Many believe the testing delay was inappropriate and she should have never been in this situation to begin with, while others believe her coaching staff should be at fault. This case has led WADA officials to indicate their desire to update the anti-doping code “before the 2026 Winter Olympics in Italy to give more powers to investigate athlete entourages.” The head of the IOC, Thomas Bach, expressed concerns over the Valieva case and stated that “doping is very rarely done alone with the athletes,” indicating a need to hold athletes’ support teams accountable. 

The World Anti-Doping Code “is the core document that harmonizes anti-doping policies, rules and regulations within sport organizations and among public authorities around the world,” and is updated every six years with the next global review set in late 2025. This review is when anti-doping violation rules may be overhauled in response to the Valieva case, especially to take into account various agencies’ requirements to investigate minor athletes’ support teams. Some changes have already been implemented since the Valieva case. Approximately four months after the 2022 Olympic Games in June 2022, the ISU voted to gradually increase the age limit for senior competitive skaters from 15 to 17. The 17 year age limit will be in effect for the 2026 Winter Olympic Games in Italy. This decision was largely believed to be in response to the Valieva controversy and an effort to better protect minors in the sport. The age limit increase is just the beginning of the overhaul in procedures and safeguards needed to protect athletes in the sport. The legal and procedural decisions by CAS, WADA, and other agencies in the coming years prior to the 2026 Winter Olympic Games are vital for the sport of figure skating to continue in a clean, fair, and legal manner.